Five Chinese innovators announced significant international partnerships on Oct 16-17
What a day for China's biotech innovation!
Five Chinese innovators announced significant international partnerships in a 24-hour window. This flurry of activity underscores the growing global demand for China-born biopharma assets.
1. Leads Biolabs & Dianthus Therapeutics forged a ~$1B global pact (ex-China) for bispecific LBL-047 (DNTH212), including $38M in upfront/near-term payments.
Read more: $1B deal follows hot IPO: Leads Biolabs and Dianthus partner on bispecific LBL-047
2. Shenzhen Pregene & Kite Pharma (a Gilead company) entered a potential $1.64B global collaboration for next-gen in vivo therapies, with a $120M upfront.
Read more: Pregene, Kite partner on next-gen therapies in potential $1.64B deal
3. Hansoh Pharmaceutical granted Roche an exclusive worldwide license (ex-China) for its CDH17-targeting ADC HS-20106 in a deal worth up to $1.53B, including an $80M upfront.
Read more: Up to $1.53B: Hansoh grants Roche an exclusive license to novel CDH17-targeting ADC HS-20110
4. Aosaikang Pharmaceutical's subsidiary AskGene licensed ASKG712 to Visara for multiple Asian markets in a potential $96M deal, with a $7M upfront.
Read more: AsK Pharm's subsidiary inks license deal with Visara for ASKG712, potentially worth $96M
5. Haihe Biopharma & Taiho Pharmaceutical announced an exclusive agreement for PI3Kα inhibitor risovalisib in Japan, with upfront and milestone payments.